Dexcom G7 15-Day CGM Clears Health Canada, Extending Wear Time for Adult Diabetics
Event summary
- Dexcom's G7 15-Day CGM received Health Canada authorization on July 13, 2026.
- The system offers up to 15.5 days of wear time, the longest in the market.
- Health Canada approval covers adults (18+) living with diabetes.
- Product not yet available for purchase; Dexcom focuses on pre-launch support.
The big picture
Dexcom's approval comes as CGM technology increasingly shifts toward longer wear times and seamless integration with daily life. The move aligns with broader trends in diabetes management toward reducing patient burden while improving clinical outcomes. With over four million Canadians living with diabetes, this authorization positions Dexcom to capture a significant portion of the country's growing demand for advanced glucose monitoring solutions.
What we're watching
- Market Penetration
- How Dexcom will leverage this approval to expand its share in Canada's diabetes management market, where over four million people are affected.
- Competitive Response
- Whether rivals like Abbott or Medtronic will accelerate their own long-wear CGM developments in response.
- Reimbursement Dynamics
- The pace at which Canadian healthcare systems adopt coverage for the extended-wear G7, given its potential to reduce sensor change frequency and costs.